{"id":27837,"date":"2023-05-05T08:00:00","date_gmt":"2023-05-05T07:00:00","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=27837"},"modified":"2025-02-26T15:13:01","modified_gmt":"2025-02-26T14:13:01","slug":"editorial-par-frederic-peyrane-et-florence-sejourne","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/","title":{"rendered":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9"},"content":{"rendered":"\n<p style=\"font-size:25px;text-transform:capitalize\"><strong>2023&nbsp;: une ann\u00e9e charni\u00e8re pour l\u2019innovation en antibior\u00e9sistance&nbsp;?<\/strong><\/p>\n\n\n\n<div style=\"height:19px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Fr\u00e9d\u00e9ric Peyrane<\/strong>, Coordinateur BEAM Alliance<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Florence S\u00e9journ\u00e9<\/strong>, Co-fondatrice BEAM Alliance et CEO Aurobac Therapeutics<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Les petites et moyennes entreprises (PME), moteurs de l\u2019innovation en antibior\u00e9sistance, pourraient d\u00e9marrer l\u2019ann\u00e9e 2023 avec le moral en berne.<\/p>\n\n\n\n<p>Nombre d\u2019entre elles ont mis la cl\u00e9 sous la porte en 2022, y compris en France, avec parfois des produits en phase de d\u00e9veloppement clinique. Autant de chances perdues d\u2019offrir aux patients et aux cliniciens des solutions nouvelles pour faire face \u00e0 la mont\u00e9e des r\u00e9sistances microbiennes.<\/p>\n\n\n\n<p>Ces \u00e9checs sont d\u2019autant plus frustrants que le besoin m\u00e9dical continue de cro\u00eetre, comme le rappelle l\u2019ECDC dans son dernier rapport. <a id=\"_ftnref1\" href=\"#_ftn1\">[1]<\/a><\/p>\n\n\n\n<p>Ces \u00e9checs refl\u00e8tent en r\u00e9alit\u00e9 une d\u00e9faillance de march\u00e9 qui rend l\u2019aire th\u00e9rapeutique de l\u2019antibior\u00e9sistance tr\u00e8s peu attractive en termes d\u2019investissements. Les PMEs ont ainsi toutes les peines du monde \u00e0 lever les fonds n\u00e9cessaires au d\u00e9veloppement de leur portefeuille de produits. Et lorsqu\u2019elles y parviennent, les montants sont si limit\u00e9s que la moindre barri\u00e8re technique ou scientifique peut s\u2019av\u00e9rer incontournable, le moindre impr\u00e9vu fatal.<\/p>\n\n\n\n<p>Pourtant, les PME continuent de garder l\u2019espoir. De jeunes pousses continuent d\u2019\u00e9merger, y compris en France.<\/p>\n\n\n\n<p>La raison&nbsp;? Les pouvoirs publics comprennent d\u00e9sormais la nature du probl\u00e8me et les enjeux associ\u00e9s. Et les gouvernements semblent pr\u00eats \u00e0 lancer les actions correctives pour redynamiser l\u2019innovation et nous permettre d\u2019anticiper la pand\u00e9mie qui s\u2019annonce.<\/p>\n\n\n\n<p>Le Royaume-Uni avait lanc\u00e9 le bal en 2019, en testant un nouveau mod\u00e8le \u00e9conomique de souscription et la Su\u00e8de lui a embo\u00eet\u00e9 le pas. Le congr\u00e8s des \u00c9tats-Unis d\u00e9bat depuis quelque temps d\u2019un projet de loi ambitieux qui s\u2019inscrit dans la m\u00eame lign\u00e9e. Le Canada et le Japon sont \u00e9galement en train de construire le m\u00e9canisme le plus adapt\u00e9 \u00e0 leurs contraintes nationales.<\/p>\n\n\n\n<p>Tous ces nouveaux m\u00e9canismes \u00e9conomiques ont un point commun&nbsp;: favoriser l\u2019usage appropri\u00e9 des antimicrobiens en garantissant une juste r\u00e9tribution pour ceux qui auront pris les risques techniques et financiers de les d\u00e9velopper.<\/p>\n\n\n\n<p>Et l\u2019Europe dans tout \u00e7a&nbsp;? Elle n\u2019est pas en reste&nbsp;! La Commission Europ\u00e9enne vient juste de publier sa proposition de r\u00e9vision de la l\u00e9gislation pharmaceutique qui introduit un m\u00e9canisme \u00e9conomique incitant l\u2019innovation. D\u2019autres m\u00e9canismes, potentiellement compl\u00e9mentaires, sont \u00e9galement \u00e0 l\u2019\u00e9tude au sein de l\u2019Autorit\u00e9 europ\u00e9enne de pr\u00e9paration et de r\u00e9action en cas d\u2019urgence sanitaire (HERA). La France, qui aura son mot \u00e0 dire comme chacun des \u00c9tats Membres, peut s\u2019appuyer sur le Comit\u00e9 Strat\u00e9gique de Fili\u00e8re, aid\u00e9 par les travaux de la Toulouse School of Economics d\u00e9velopp\u00e9s au sein du projet ARPEGE, pour se forger une opinion.<\/p>\n\n\n\n<p>La solution pourrait donc \u00eatre \u00e0 port\u00e9e de main. Une solution pour relancer la machine \u00e0 innover et prolonger ce miracle engendr\u00e9 par les antibiotiques&nbsp;o\u00f9 les infections microbiennes restent un \u00e9v\u00e8nement passager et b\u00e9nin.<\/p>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><em><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> European Centre for Disease Prevention and Control (ECDC): Antimicrobial resistance in the EU\/EEA (EARS-Net) &#8211; Annual epidemiological report for 2021 (disponible sur le <a href=\"https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2021\">site de l\u2019ECDC<\/a>)<\/em><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Auteurs<\/h3>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:41% auto\"><figure class=\"wp-block-media-text__media\"><img fetchpriority=\"high\" decoding=\"async\" width=\"542\" height=\"639\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Frederic-Peyrane.png\" alt=\"\" class=\"wp-image-30146 size-full\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Frederic-Peyrane.png 542w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Frederic-Peyrane-254x300.png 254w\" sizes=\"(max-width: 542px) 100vw, 542px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong><strong>Fr\u00e9d\u00e9ric Peyrane<\/strong><\/strong><\/p>\n\n\n\n<p><em>Coordinateur BEAM Alliance<\/em><\/p>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:41% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"552\" height=\"639\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Florence-Sejourne.png\" alt=\"\" class=\"wp-image-30148 size-full\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Florence-Sejourne.png 552w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/Florence-Sejourne-259x300.png 259w\" sizes=\"(max-width: 552px) 100vw, 552px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong><strong>Florence S\u00e9journ\u00e9<\/strong><\/strong><\/p>\n\n\n\n<p><em>Co-fondatrice BEAM Alliance et CEO Aurobac Therapeutics<\/em><\/p>\n<\/div><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les petites et moyennes entreprises (PMEs), moteur de l\u2019innovation en antibior\u00e9sistance, pourraient d\u00e9marrer l\u2019ann\u00e9e 2023 avec le moral en berne.<\/p>\n<p>Nombre d\u2019entre elles ont mis la cl\u00e9 sous la porte en 2022, y compris en France, avec parfois des produits en phase de d\u00e9veloppement clinique. Autant de chances perdues d\u2019offrir aux patients et aux cliniciens des solutions nouvelles pour faire face \u00e0 la mont\u00e9e des r\u00e9sistances microbiennes.<\/p>\n","protected":false},"author":271,"featured_media":27839,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[3341],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-05T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T14:13:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1095\" \/>\n\t<meta property=\"og:image:height\" content=\"639\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Loane Serrano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Loane Serrano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\"},\"author\":{\"name\":\"Loane Serrano\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61\"},\"headline\":\"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9\",\"datePublished\":\"2023-05-05T07:00:00+00:00\",\"dateModified\":\"2025-02-26T14:13:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\"},\"wordCount\":590,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg\",\"articleSection\":[\"Editoriaux\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\",\"name\":\"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg\",\"datePublished\":\"2023-05-05T07:00:00+00:00\",\"dateModified\":\"2025-02-26T14:13:01+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg\",\"width\":1095,\"height\":639,\"caption\":\"Gauche: Fr\u00e9d\u00e9ric Peyrane Droite: Florence S\u00e9journ\u00e9\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editoriaux\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61\",\"name\":\"Loane Serrano\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/","og_locale":"fr_FR","og_type":"article","og_title":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2023-05-05T07:00:00+00:00","article_modified_time":"2025-02-26T14:13:01+00:00","og_image":[{"width":1095,"height":639,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg","type":"image\/jpeg"}],"author":"Loane Serrano","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Loane Serrano","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/"},"author":{"name":"Loane Serrano","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61"},"headline":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9","datePublished":"2023-05-05T07:00:00+00:00","dateModified":"2025-02-26T14:13:01+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/"},"wordCount":590,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg","articleSection":["Editoriaux"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/","name":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg","datePublished":"2023-05-05T07:00:00+00:00","dateModified":"2025-02-26T14:13:01+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/05\/tinywow_F.-PEYRANE_21879231.jpg","width":1095,"height":639,"caption":"Gauche: Fr\u00e9d\u00e9ric Peyrane Droite: Florence S\u00e9journ\u00e9"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/editorial-par-frederic-peyrane-et-florence-sejourne\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Editoriaux","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/"},{"@type":"ListItem","position":3,"name":"Editorial par Fr\u00e9d\u00e9ric Peyrane et Florence S\u00e9journ\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61","name":"Loane Serrano"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-21 22:13:48","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/27837"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/271"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=27837"}],"version-history":[{"count":10,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/27837\/revisions"}],"predecessor-version":[{"id":30150,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/27837\/revisions\/30150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/27839"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=27837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=27837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=27837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}